FDA 483 - GVK Biosciences Pvt. Ltd. - March 13, 2015
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Clinogent (Div of GVK Biosciences) in Hyderabad, India, a Clinical Pharmacological Unit, revealed significant deficiencies in record-keeping and study documentation. Observations included issues with electronic ECG records, lack of adverse event evaluations, missing drug screening assay information, and inadequate maintenance of correspondence files. These findings highlight concerns regarding data integrity and the proper conduct of clinical studies.
- Person
ID · 5f43791a-4ab0-45af-9712-99c86ae216de